Harmony Biosciences Holdings, Inc.

NASDAQ:HRMY

Biotechnology

Healthcare
$33.11 -1.81%

-$0.61 today

Market cap
$1.94B
Beta
0.97
P/E (TTM)
13.2
EPS (TTM)
$2.52
52W Low $25.52High $40.87

Volume 0.57M

Average 0.82M

HRMY Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Harmony Biosciences Holdings, Inc.NASDAQ: HRMY

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income growth accelerates

Q2 FY2026 net income of $75.43M rose 89.6% year over year, ahead of the +0.2% change in trailing-twelve-month net income. Sequentially, it rose 132.2% from the prior quarter. Over 3 fiscal years it compounded at -4.4% a year.

Context

  • Net income amounted to 18.3% of revenue in FY2025, down 2.1 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 9 analysts of $208.75M (+31.6%) for the fiscal year ending Dec 2026, a step up from the +9.1% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$75.43M+132.2% QoQ
Last fiscal yearDec 2025
$158.69M+9.1% YoY
LTMJun 2026
$181.27M+0.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+89.6%+27.6%-62.0 pp
1 year+9.1%+31.6%+22.5 pp
3-year CAGR-4.4%+24.0%+28.4 pp
5-year CAGR+13.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
158.69M USD
Year-over-year change
+9.1%
4-year CAGR
+46.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How HRMY compares with its peers on the latest reported figures

  • HRMY's LTM Jun 2026 net income of $181.27M is the 2nd largest of the 4 companies compared; the peer median is $178.8M.
  • Its year-over-year change of +0.2% is the lowest of 2, against a peer median of +29.8%.
  • Net income amounts to 18.9% of revenue for HRMY.
HRMY Competitors Peer median
Net Income for HRMY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NERVMinerva Neurosciences, Inc.LTM Jun 2026$108.22B —+109.1%—
HRMYHarmony Biosciences Holdings, Inc.LTM Jun 2026$181.27M +0.2%-4.4%18.9%
CMPSCOMPASS Pathways plcLTM Mar 2026$178.8M +29.8%+46.5%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$39.17M —+20.7%—
APMDApnimed, Inc.—— ———
Peer median (excluding HRMY) $178.8M+29.8%+46.5%—

Competitors are the stored peer set for HRMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income34.6M181.47M128.85M145.49M158.69M
Depreciation & Amortization18.84M23.39M24.36M24.11M25.34M
Deferred Income Tax00(13.42M)(29.3M)0
Stock-Based Compensation16.11M26.91M31.71M42.6M44.9M
Change in Working Capital2.19M(6.89M)35.04M(7.32M)91.82M
Accounts Receivables(12.67M)(19.9M)(19.4M)(8.89M)(13.75M)
Inventory(609K)135K(1.07M)(1.84M)1.84M
Accounts Payables008.95M(5.38M)3.95M
Other Working Capital15.46M12.87M46.55M8.79M99.78M
Other Non-Cash Items26.83M(80.4M)12.85M44.23M27.47M
Operating Cash Flow98.56M144.47M219.39M219.82M348.2M
Capital Expenditures(298K)(172K)(312K)(1.15M)(310K)
Acquisitions (Net)00(36.97M)(33.07M)0
Purchases of Investments00(127.47M)(105.29M)(86.15M)
Sales of Investments00118.31M98.53M81.06M
Other Investing Activities(100M)(141.66M)0(26.5M)(15M)
Investing Cash Flow(100.3M)(141.83M)(46.44M)(67.48M)(39.65M)
Debt Repayment(500K)(2M)(1.25M)(15M)(16.25M)
Common Stock Issued0006.5M10.21M
Common Stock Repurchased00(100M)00
Dividends Paid00000
Other Financing Activities7.92M8.84M(3.79M)(2.5M)(3M)
Financing Cash Flow7.42M6.84M(105.55M)(11M)(9.05M)
Effect of Forex Changes00000
Net Change in Cash5.68M9.48M67.4M141.34M299.5M
Free Cash Flow98.26M144.29M219.08M218.67M347.89M

Harmony Biosciences Holdings, Inc.

NASDAQ:HRMY

Intrinsic Alpha fair value

Locked

Current Price

$33.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.